Printer Friendly Version View printer-friendly version
<< Back
Ocular Therapeutix™ to Present Data at the American Society of Cataract and Refractive Surgery (ASCRS) Symposium

BEDFORD, Mass.--(BUSINESS WIRE)--Apr. 9, 2018-- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced data from its clinical and preclinical research will be highlighted in presentations at the combined American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators (ASCRS-ASOA) Symposium, April 13 -17, in Washington D.C. The presentations include clinical data for lead product candidate DEXTENZA™ (dexamethasone insert) 0.4 mg, for the treatment of pain following ophthalmic surgery, and pre-clinical data for product candidate OTX-TIC (travoprost implant), an intracameral injection for the reduction of intraocular pressure in patients with glaucoma and ocular hypertension.

“The presentations at ASCRS-ASOA highlight clinical data with DEXTENZA for treating patients following ophthalmic surgery and provide insight into the physician and patient experience with the product,” said Michael Goldstein, M.D., Chief Medical Officer of Ocular Therapeutix. “While our primary focus continues to be the resubmission of DEXTENZA in the second quarter of 2018, we are also excited about the progress of our pipeline product candidates including the pre-clinical data we are seeing with OTX-TIC for the treatment of glaucoma.”

Paper Presentations at ASCRS-ASOA, Washington, D.C.:

  • Preclinical Assessment of OTX-TIC (travoprost) Biodegradable Hydrogel Intracameral Depot for the Treatment of Glaucoma. Blizzard C.
    Sunday, April 15, 2018; 3:02 PM3:07 PM
    Walter E. Washington Convention Center – Level 1, 144B
  • Integrated Analysis of Efficacy and Safety of Dexamethasone Insert (0.4 mg) for the Treatment of Ocular Pain and Inflammation after Cataract Surgery. Berdahl J.
    Monday, April 16, 2018; 1:41 PM1:46 PM
    Walter E. Washington Convention Center – Level 1, 143B
  • Evaluating the Physician and Patient Experience of a Dexamethasone Insert (0.4 mg) in Patients Having Cataract Surgery. Noecker R.
    Monday, April 16, 2018; 2:13 PM2:18 PM
    Walter E. Washington Convention Center – Level 1, 143B

About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary hydrogel-based formulation technology. Ocular Therapeutix’s lead product candidate, DEXTENZA™ (dexamethasone insert) 0.4 mg for intracanalicular use, has completed Phase 3 clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery. OTX-TP (travoprost insert) is in Phase 3 clinical development for the reduction of intraocular pressure in patients with glaucoma and ocular hypertension. The Company’s earlier stage assets include OTX-TIC, a sustained release travoprost intracameral implant for the reduction of intraocular pressure in patients with glaucoma and ocular hypertension, as well as sustained release intravitreal implants for the treatment of retinal diseases. These implants include the development of OTX-TKI, a tyrosine kinase inhibitor (TKI), and, in collaboration with Regeneron, an extended release protein-based anti-vascular endothelial growth factor (VEGF) trap. Ocular Therapeutix's first product, ReSure® Sealant, is FDA-approved to seal corneal incisions following cataract surgery.

About DEXTENZA™ (dexamethasone insert) 0.4 mg for Intracanalicular Use
DEXTENZA is a corticosteroid intracanalicular insert placed through the punctum, a natural opening in the eye lid, into the canaliculus and is designed to deliver dexamethasone to the ocular surface for up to 30 days without preservatives. Following treatment, DEXTENZA is intended to resorb and exit the nasolacrimal system without the need for removal.

About OTX-TIC (travoprost implant) for Intracameral Use
OTX-TIC is designed to be a bioresorbable implant containing micronized travoprost that is injected into the anterior chamber of the eye, with a target duration of drug delivery of three to four months. Preclinical studies in beagles have demonstrated sustained intraocular pressure lowering and maintenance of drug levels in the aqueous humor.

Forward Looking Statements
Any statements in this press release about future expectations, plans and prospects for the Company, including the development and regulatory status of the Company’s product candidates, such as the Company’s regulatory submissions for and the timing and conduct of, or implications of results from, clinical trials of DEXTENZA™ for the treatment of post-surgical ocular inflammation and pain, including with respect to manufacturing deficiencies identified by the Food and Drug Administration (FDA), the Company’s expectations regarding resubmitting its NDA to the FDA and the prospects for approvability of DEXTENZA for these indications, DEXTENZA for the treatment of allergic conjunctivitis, DEXTENZA for the treatment of dry eye disease and OTX-TP for the treatment of glaucoma and ocular hypertension, the ongoing development of the Company’s sustained release hydrogel depot technology, the potential utility of any of the Company’s product candidates, potential commercialization of the Company’s product candidates, the potential benefits and future operation of the collaboration with Regeneron Pharmaceuticals, including any potential future payments thereunder, the sufficiency of the Company’s cash resources and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend", "goal," "may", "might," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors. Such forward-looking statements involve substantial risks and uncertainties that could cause the Company’s clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, those related to the timing and costs involved in commercializing ReSure® Sealant or any product candidate that receives regulatory approval, the initiation and conduct of clinical trials, availability of data from clinical trials and expectations for regulatory submissions and approvals, the Company’s scientific approach and general development progress, the availability or commercial potential of the Company’s product candidates, the sufficiency of cash resources, the outcome of the Company’s ongoing legal proceedings and need for additional financing or other actions and other factors discussed in the “Risk Factors” section contained in the Company’s quarterly and annual reports on file with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the Company’s views as of the date of this release. The Company anticipates that subsequent events and developments will cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of this release.

Source: Ocular Therapeutix, Inc.

Investors
Ocular Therapeutix
Donald Notman
Chief Financial Officer
dnotman@ocutx.com
or
Westwicke Partners
Chris Brinzey
Managing Director
chris.brinzey@westwicke.com
or
Media
Ocular Therapeutix
Scott Corning
Senior Vice President, Commercial
scorning@ocutx.com